Alzheimer's disease hypothesis and related therapies.

Du X, Wang X, Geng M. · 2018

Read Alzheimer's disease hypothesis and related therapies. by Du X, Wang X, Geng M. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5789526.txt.

Introduction

Du, Wang, and Geng review the main hypotheses for Alzheimer disease and the therapies built on them. The disease is the most common cause of dementia. Only five drugs have won approval, and they ease symptoms briefly at best. Fresh ideas are badly needed.

The review covers amyloid deposits outside neurons and tau tangles inside them. It also covers cholinergic damage, inflammation, and oxidative stress. For each idea, drugs in use or in testing are set out. The authors weigh what each path has delivered and where work heads next.

Catalog record

CREATORDu X, Wang X, Geng M.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE41 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5789526

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Alzheimer’s disease hypothesis and related therapies By Xiaoguang Du, Xinyi Wang, Meiyu Geng Published in: Translational Neurodegeneration DOI: 10.1186/s40035-018-0107-y ABSTRACT Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause for dementia. There are many hypotheses about AD, including abnormal deposit of amyloid β (Aβ) protein in the extracellular spaces of neurons, formation of twisted fibers of tau proteins inside neurons, cholinergic neuron damage, inflammation, oxidative stress, etc., and many anti-AD drugs based on these hypotheses have been developed. In this review, we will discuss the existing and emerging hypothesis and related therapies. BACKGROUND Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, which is the most common cause for dementia and imposes immense suffering on patients and their families. According to the World Alzheimer Report 2016, there are currently about 46.8 million people suffering with AD worldwide. The ageing of world population will further compound this problem and lead to a steep increase in the number of AD patients. The numbers of AD patients are expected to double nearly every 20 years, and thereby the population of AD will reach 74.7 million in 2030 and 131.5 million in 2050 [1]. AD has become the third major cause of disability and death for the elderly, only after cardiovascular and cerebrovascular diseases and malignant tumors. However, only five drugs have been approved by the FDA to treat AD over the past hundred years since the first AD patient was diagnosed. Not only that, these approved drugs including cholinesterase inhibitors, N-methyl-D-aspartate (NMDA) receptor antagonist or their combination usually provide temporary and incomplete symptomatic relief accompanied with severe side effects. The marginal benefits were unable to slow the progression of AD. Thus, developing drugs for more effective AD treatment is in urgent need. Current hypothesis about AD and anti-AD drug development AD is a complicated disease involving many factors. Due to the complexity of human brains, the lack of reasonable animal models and research tools, the detailed pathogenesis of AD is still unclear so far. Many hypotheses about AD have been developed, including amyloid β (Aβ), Tau, cholinergic neuron damage and oxidative stress, inflammation, etc. Thus, many efforts have been done to develop anti-AD drugs based on these hypotheses. Aβ cascade hypothesis Extracellular deposits of Aβ peptides as senile plaques, intraneuronal neurofibrillary tangles (NFTs), and large-scale neuronal loss were the main pathological features of AD. Thus, Aβ peptides have long been viewed as a potential target for AD which dominated new drug research during the past twenty years [2]. The most direct strategy in anti-Aβ therapy is to reduce Aβ production by targeting β- and γ-secretase [3]. Safety issues are the overriding problem. For targeting γ-secretase, undesirable side effects are inevitable due to its physiological substrates, eg. the Notch signaling protein [4–7], which is essential in normal biological process. Similarily, targeting β-secretase is also challenged for the side effects such as blindness and the large catalytic pocket [8]. More importantly, in sporadic AD cases, the majority of AD patients do not necessarily have over-producted amyloid precursor protein. Besides, Aβ isoforms could also serve as endogenous positive regulators for neurotransmitter release at hippocampal synapses [9]. Thus, inhibiting Aβ production may encounter many challenges. Aβ clearance by immunotherapy is the alternative choice. For active Aβ-immunotherapy, although the first active AD vaccine (AN1792) developed by ELAN showed some beneficial effects such as less cognitive decline, it was suspended owing to serious side effect, or meningoencephalitis [10–12]. Also, the passive immunotherapy did not do much better than active immunotherapy. Several antibodies targeting Aβ have failed in clinical trials, including bapineuzumab (Pfizer/Johnson & Johnson) [13, 14], Crenezumab (Genentech) [15, 16], solanezumab (Eli Lilly) [16–18] and ponezumab (Johnson & Johnson /Pfizer) [19–21]. In addition, although passive immunotherapy could overcome some problems of active immunotherapy, there were still inevitable side effects such as amyloid-related imaging abnormalities [22]. Likewise, the small molecule Aβ binder scyllo-inositol [23] and tramiprosate [24–26] also failed in clinical trials. These failures even cast more doubts on the Aβ theory [27]. Actually, the strategy of targeting only a single functional subregion of Aβ may partly account for these failures [27, 28]. Furthermore, immunotherapy may influence the human immune system, which might cause beneficial or detrimental consequence (such as side effects). However, every cloud has a silver lining. A phase Ib trial of aducanumab (Biogen) showed a positive correlation between brain Aβ levels and disease exacerbation as measured by Clinical Dementia Rating [29–31]. Even the failed phase III EXPEDITION3 trial of solanezumab (Eli Lilly) still demonstrated better performance in Clinical Dementia Rating Sum of Boxes and beneficial impacts on Mini-Mental State Examination and Activities of Daily Living [17, 18, 32, 33]. Thus, despite all kinds of problems, immunotherapy may still be the better approach to modify the extent of neurodegeneration in AD currently [34]. In fact, the original amyloid cascade hypothesis was that “Aβ is the causative agent in Alzheimer’s Disease pathology, and that neurofibrillary tangles, cell loss, vascular damage, and dementia follow as a direct result of this deposition” [35]. After decades of research, although the bulk of data still supports a role for Aβ as the primary initiator of the complex pathogenic cascade in AD, more and more evidences indicate that Aβ acts as a trigger in the early disease process and appears to be necessary but not sufficient in the late stage of AD [36]. Especially, recent rapid progresses in understanding on toxic amyloid assembly and Aβ metabolism associated systemic abnormalities will provide fresh impetus and new opportunities for this interesting approach [37]. Tau hypothesis Neurofibrillary tangles, another intracellular hallmark of AD, are composed of tau. Tau is a microtubule-associated protein working as scaffolding proteins that are enriched in axons. In pathological conditions, tau aggregation will impair axons of neurons and thus cause neurodegeneration. After numerous failures of Aβ-targeting drugs for AD, more interests are turning to explore the therapeutic potential of targeting tau, particularly as studies of biomarkers suggest that tau pathology is more closely linked to the progression of AD [38]. Tau undergoes many modifications, including phosphorylation, arginine monomethylation, lysine acetylation, lysine monomethylation, lysine dimethylation, lysine ubiquitylation and serine. O-linked N-acetylglucosamine (O-GlcNAc) modification [39]. Under pathological conditions, increasing of tau hyperphosphorylation will render the protein aggregation-proned, reduce its affinity for microtubules, and thereby influence neuronal plasticity. Consequently, strategies to target tau involve blocking of tau aggregation, utilizing tau vaccinations, stabilizing microtubules, manipulating kinases and phosphatases that govern tau modifications. However, most of these efforts have failed in clinical trials. For Tau aggregation blockers, TRx0237 failed to show treatment benefits in phase III trials [40]. As for vaccinations, tau-targeted active vaccines (ACI35 and AADvac-1) and passive vaccines (RG6100 and ABBv-8E12) are currently in phase I and II clinical trials [41, 42]. Intravenous immunoglobulin (IVIG), the only passive vaccine in phase III clinical trials, failed to meet the primary end points in patients with mild-to-moderate AD [42]. Other tau-targeting strategies for AD, including stabilizing microtubules and manipulating kinases and phosphatases, have just been tested in preclinical studies. In general, tau-targeting therapies remain challenging because of incomplete understanding of AD, lack of robust and sensitive biomarkers for diagnosis and response-monitoring, and the obstruction of blood-brain barrier. Inflammation hypothesis Reactive gliosis and neuroinflammation are hallmarks

Read the complete text